ReAlta Life Sciences’ RLS-0071 Gains the US FDA’s ODD & FTD to Treat Steroid-Refractory aGvHD
Shots:
- The US FDA has granted Orphan Drug Designation (ODD) & Fast Track Designation (FTD) to the company’s RLS-0071 for treating steroid-refractory acute graft-versus-host disease (aGvHD) in hospitalized individuals.
- RLS-0071 is presently an ongoing P-II open-label study for treating hospitalized individuals who have steroid-refractory aGvHD
- Additionally, the company is presently carrying out a P-II study for RLS-0071 in newborns suffering from hypoxic-ischemic encephalopathy (HIE) and in hospitalized individuals experiencing acute exacerbations of chronic obstructive pulmonary disease.
Ref: ReAlta Life Sciences | Image: ReAlta Life Sciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
